美国FDA一位发言人4月7日宣布FDA有条件的批准了Glaxo Smith K1ine公司将减肥药赛尼可（Xenical）作为非处方类药物销售。美国FDA发言人Laura Alvey女士说，英国制药商已经在周四（4月6日）接到了FDA关于该药（将用Alli作为商标销售）...美国FDA一位发言人4月7日宣布FDA有条件的批准了Glaxo Smith K1ine公司将减肥药赛尼可（Xenical）作为非处方类药物销售。美国FDA发言人Laura Alvey女士说，英国制药商已经在周四（4月6日）接到了FDA关于该药（将用Alli作为商标销售）的通知。但是她并没有透露该公司必须采取怎样的措施才能获得最终批准。展开更多
Chylous ascites is uncommon and occurs in about 1 in 20,000 hospital admissions. Causes include disruption of the lymphatic system due to malignancy, cirrhosis, surgery, or radiation therapy. The mainstay of therapy h...Chylous ascites is uncommon and occurs in about 1 in 20,000 hospital admissions. Causes include disruption of the lymphatic system due to malignancy, cirrhosis, surgery, or radiation therapy. The mainstay of therapy has been low-fat diet supplemented with medium-chain triglyceride oil. However, dietary compliance can be difficult to achieve for adequate response. We report a 47-year-old man with hepatitis C and alcohol-related cirrhosis with new-onset chylous ascites and chylothorax. His ascites triglyceride was 585 mg/dL, and the pleural fluid triglyceride was 691 mg/dL. Ascitic and pleural fluid cytology and acid-fast bacilli stain were negative. The patient was treated with low-fat diet and medium-chain triglyceride oil. However, his ascites remained chylous after 1 week of treatment because of poor compliance with the dietary restrictions. Orlistat was then added to his treatment regimen. A half week later, the chylous component of his ascites resolved. Remaining high-volume clear ascites was treated with placement of a transjugular intrahepatic portosystemic shunt. To our knowledge, orlistat has never been used in the treatment of chylous ascites. This case suggests the potential value of adding orlistat to lowfat diet and medium-chain triglyceride oil in the treatment of chylous ascites, especially in patients who are unable to comply with the dietary restrictions.展开更多
文摘美国FDA一位发言人4月7日宣布FDA有条件的批准了Glaxo Smith K1ine公司将减肥药赛尼可（Xenical）作为非处方类药物销售。美国FDA发言人Laura Alvey女士说，英国制药商已经在周四（4月6日）接到了FDA关于该药（将用Alli作为商标销售）的通知。但是她并没有透露该公司必须采取怎样的措施才能获得最终批准。
文摘Chylous ascites is uncommon and occurs in about 1 in 20,000 hospital admissions. Causes include disruption of the lymphatic system due to malignancy, cirrhosis, surgery, or radiation therapy. The mainstay of therapy has been low-fat diet supplemented with medium-chain triglyceride oil. However, dietary compliance can be difficult to achieve for adequate response. We report a 47-year-old man with hepatitis C and alcohol-related cirrhosis with new-onset chylous ascites and chylothorax. His ascites triglyceride was 585 mg/dL, and the pleural fluid triglyceride was 691 mg/dL. Ascitic and pleural fluid cytology and acid-fast bacilli stain were negative. The patient was treated with low-fat diet and medium-chain triglyceride oil. However, his ascites remained chylous after 1 week of treatment because of poor compliance with the dietary restrictions. Orlistat was then added to his treatment regimen. A half week later, the chylous component of his ascites resolved. Remaining high-volume clear ascites was treated with placement of a transjugular intrahepatic portosystemic shunt. To our knowledge, orlistat has never been used in the treatment of chylous ascites. This case suggests the potential value of adding orlistat to lowfat diet and medium-chain triglyceride oil in the treatment of chylous ascites, especially in patients who are unable to comply with the dietary restrictions.
